Ganga Pharmaceuticals Ltd. (GANGAPHARM) — Tipsheet https://tipsheet.markets/company/gangapharm/ Every Tipsheet Editorial note covering Ganga Pharmaceuticals Ltd. (GANGAPHARM), newest first. Grounded in BSE/NSE primary-source filings. en-in Mon, 06 Jul 2026 10:22:47 GMT Ganga Pharma's FY26 results show modest uptick, no surprises https://tipsheet.markets/gangapharm-ganga-pharma-s-fy26-results-show-modest-uptick-no-surprises-94245/ https://tipsheet.markets/gangapharm-ganga-pharma-s-fy26-results-show-modest-uptick-no-surprises-94245/ Thu, 21 May 2026 16:36:21 GMT Revenue rose to ₹282.79 lakhs, net profit to ₹10.15 lakhs; clean audit opinion keeps the filing routine for the nano-cap. Revenue rose to ₹282.79 lakhs, net profit to ₹10.15 lakhs; clean audit opinion keeps the filing routine for the nano-cap.

What’s new

  • Revenue inched up to ₹282.79 lakhs from ₹263.74 lakhs
  • Net profit rose 28% to ₹10.15 lakhs from ₹7.90 lakhs
  • Auditor issued an unmodified opinion; no profit warnings or guidance changes

Why it matters

For a nano-cap with a ₹7 crore market cap, these are routine results that carry no market-moving news. The modest improvement and clean audit provide no reason for material share price action.

What we’re watching

  • Next quarter's revenue trajectory to see if growth sustains
  • Any future guidance from management on scaling operations

The full read

Ganga Pharmaceuticals reported a modest uptick in its audited FY26 numbers. Revenue inched up to ₹282.79 lakhs and net profit to ₹10.15 lakhs, both marginally higher than the prior year. The auditor issued a clean opinion. For a company with a market cap just over ₹7 crore, the results are routine and contain no surprises that would move the stock.

Primary source: BSE · NSE

]]> Earnings Tipsheet Editorial Ganga Pharma FY26 revenue inches up 7% to ₹282.79 lakhs https://tipsheet.markets/gangapharm-ganga-pharma-fy26-revenue-inches-up-7-to-282-79-lakhs-94214/ https://tipsheet.markets/gangapharm-ganga-pharma-fy26-revenue-inches-up-7-to-282-79-lakhs-94214/ Thu, 21 May 2026 16:27:32 GMT Net profit jumps 28% to ₹10.15 lakhs; auditor issues clean opinion. Routine filing for the nano-cap. Net profit jumps 28% to ₹10.15 lakhs; auditor issues clean opinion. Routine filing for the nano-cap.

What’s new

  • Revenue from operations rose to ₹282.79 lakhs, up 7% from FY25.
  • Net profit climbed 28% to ₹10.15 lakhs.
  • Auditor issued unmodified opinion; no guidance changes.

Why it matters

For a nano-cap with a ₹7-crore market cap, these results are routine and unlikely to alter the stock's trajectory. The modest growth and clean audit provide no negative surprises, but also no catalysts. The key remains how the company deploys warrant conversion proceeds.

What we’re watching

  • Progress on utilization of warrant conversion proceeds.
  • Whether revenue growth accelerates in H1 FY27.
  • Any new order wins or product launches.

The full read

Ganga Pharmaceuticals turned in a steady but unexciting FY26. Revenue inched up 7% to ₹282.79 lakhs, while net profit jumped 28% to ₹10.15 lakhs, partly due to a low base. The auditor gave an unmodified opinion, and no guidance changes were made. For a ₹7-crore market-cap company, these numbers are too small to move the needle. The real focus is on the already-disclosed warrant conversion — the company has cash to deploy, but investors have yet to see returns from that capital. Until that changes, the stock is likely to drift.

Primary source: BSE · NSE

]]> Earnings Tipsheet Editorial